Q1 2026 Digital Health Trends: The Age of Proof
Capital is concentrating. Buyers demand evidence. And only the most operationally sound companies are winning.
A data-driven analysis of funding, exits, and the structural shifts redefining global digital health.
Inside the report: Capital Concentration: Fewer deals, larger checks, higher expectations Geographic Shifts: North America dominance amid global volatility Category Battlegrounds: Health management, patient solutions, and wellness The Evidence Standard: Clinical validation and real-world outcomes as gating factors The End of Pilots: Embedded, contractual partnerships replacing experimentation
Complete the form to access the full analysis.Purpose & Scope
Objective
Identify leading early-stage digital health ventures demonstrating forward-looking momentum.
Intended Audience
Investors, Corporate Strategy, Pharma BD, Health Systems, Corporate Digital Health.
Geographic Scope
Global
Sector Scope
Digital Health innovation only iaw the HealthTech Alpha Digital Health taxonomy.
Exclusions
Biotech (pure drug discovery), non-digital devices, acquired ventures.
Data Sources & Signals
Data Source: HealthTech Alpha
Platform Coverage
Structured AI-powered Digital Health intelligence.
Companies Covered
50,000+
Investors Covered
16,000+
Corporates Covered
15,000+
Update Frequency
Real-time structured refresh.
Timeframe of Analysis
Funding Signals
Jan 2023 – Dec 2025
Partnership Signals
Jan 2023 – Dec 2025
Evidence Signals
Jan 2023 – Dec 2025
Snapshot Date
1-Feb-26
Definitions
Early Stage
Pre-Seed, Seed, Series A
Growth Stage
Series B–C
Late Stage
Series D+
Evidence Signal™
Structured measure of validation and regulatory progress.
Alpha Score
Composite maturity metric.
Scoring and Selection Process
Selection Framework (High-Level)
Quantitative Signals
Funding velocity, partnership density, evidence indicators.
Momentum Criteria
Recent raise or partnership, signal acceleration.
Qualitative Review
Analyst validation layer.
Exclusions
Acquired, inactive, insufficient transparency.
How to Use This Dataset
Deal Sourcing
Identify high-momentum ventures.
Competitive Benchmarking
Compare portfolio exposure.
M&A Radar
Monitor scale-ready targets.
Corporate Innovation
Identify validated partners.
Universe Definition
Incorporation Window
2021 – Present
Funding Stage Eligibility
Pre-Seed, Seed, Series A
Funding Stage Exclusion
Series B and later excluded
Venture Type
Digital Health ventures only
Stage 1 – Waterfall Filtering
Incorporation Date Filter
Between 1 January 2021 and snapshot date
Funding Stage Filter
No higher than Series A
Active Status
Must not be acquired or inactive
Data Sufficiency
Minimum structured signal coverage required
Stage 2 – Weighted Analysis & Geography Normalization
Purpose
Rank eligible ventures using composite weighted scoring.
Geography Normalization
Percentile benchmarking within comparable regions.
Weighted Metrics Framework
| Metric | Weight | Description |
|---|---|---|
| 2025 Relevance | 25% | Alignment with top trending Digital Health themes of 2025. |
| Alpha Score | 15% | Proprietary composite maturity assessment. |
| Clinical Evidence Signal | 15% | Assessment of validation and regulatory progress. |
| Funding Value Percentile | 10% | Capital raised percentile relative to stage and geography. |
| Funding Velocity | 10% | Speed of capital accumulation since incorporation. |
| Partnership Signal | 10% | Measured ecosystem engagement activity. |
| Health Check | 15% | Composite structural robustness indicator. |
Adjustments vs Previous Edition
Weighting Update
Weighting matrices moderately refined compared to prior editions.
Rationale
Reflect evolving ecosystem dynamics and 2025 thematic shifts.
Scoring Outcome
Composite Score
Weighted aggregate of all Stage 2 metrics.
Final Selection
Top early-stage ventures ranked by normalized composite score.
Important Notes
Not Investment Advice
This ranking does not constitute investment recommendation.
Data Limitation
Based on structured disclosed data as of snapshot date.
Who Is It For?
Intended Audience
Investors, Corporate Strategy, Pharma BD, Health Systems, and Corporate Digital Health teams.
Primary Use Cases
Rapid shortlisting, benchmarking, and ongoing market tracking of digital health funding and investment trends.
Clusters & Therapeutic Areas
The cohort reflects a balance between disease-specific innovation and cross-therapeutic platforms, with a substantial share of startups operating in a disease-agnostic capacity. Among targeted areas, Oncology leads (16%), followed by Women’s Health (8%) and Mental Health (6%), with Cardiovascular and Wellness each at 5%. From a solution perspective, Health Management Solutions (24%) dominate, followed by Medical Diagnostics (16%) and Research Solutions (15%). Smaller but relevant clusters include Patient Solutions (8%), Wellness (7%), and Telemedicine (6%), reflecting a shift toward outcome-driven, infrastructure-oriented models.
Leading Digital Health Categories
The HealthTech 250 spans a broad range of digital health categories, with strong representation in health management solutions, diagnostics, and research. Compared with prior years, the 2026 cohort shows a clear shift toward ventures that integrate directly into clinical workflows or enable measurable operational improvements for healthcare providers, payers, and life sciences companies.Therapeutic Area Distribution
From a therapeutic perspective, the 2026 cohort is led by oncology, women’s health, mental health, and cardiometabolic conditions. These areas combine large patient populations with clear unmet needs and strong commercial interest, making them attractive for both investors and strategic partners. The distribution reflects a broader industry trend toward condition-specific solutions that demonstrate clinical impact and economic value.Funding Landscape
The cohort raised approximately USD 1.5--1.6 billion with an average deal size of USD 26.3 million. As of January 2026, the cohort maintains a 96% survival rate. Stand-out rounds include Function Health ($298M), Profluent ($106M), Paradigm ($78M), Nourish ($70M), and CertifyOS ($40M).